FrancophonIA/ELRC3.0 huggingface dataset:
English: Following reconstitution of the immune system in immunocompromised patients with PML,
Slovenian: Po okrevanju imunskega sistema pri imunsko oslabljenih bolnikih s PML so opazili stabilizacijo ali izboljšanje izida.
English: The ORR was 36% (CI95% 21% - 51%; CR 3%, PR 33%) with a median TTP for responding patients of 9.6 months (range 4.5 to 26.8 months).
Slovenian: Celokupen odgovor je znašal 36% (95-% interval zaupanja 21-51%; popoln odgovor 3%, delni odgovor 33%); mediana časa do napredovanja bolezni je za odzivne bolnike znašala 9,6 meseca (razpon 4,5 do 26,8 meseca).
English: Ritemvia is used for the treatment of patients with moderate to severe pemphigus vulgaris.
Slovenian: Zdravilo Ritemvia se uporablja za zdravljenje bolnikov z zmernim do hudim navadnim pemfigusom.
English: Cardiovascular reactions during clinical trials with rituximab monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension.
Slovenian: O kardiovaskularnih neželenih učinkih so med kliničnimi preskušanji rituksimaba kot samostojnega zdravila poročali pri 18,8% bolnikov.
English: Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years.
Slovenian: V okviru vzdrževalnega zdravljenja so bolniki prejeli eno infuzijo rituksimaba v odmerku 375 mg/m2 telesne površine vsaka 2 meseca do napredovanja bolezni ali največ dve leti.
English: Event-free survival (median)
Slovenian: EFS: preživetje brez dogodka (Event Free Survival)
English: Contraindications for use in rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris
Slovenian: Kontraindikacije za uporabo pri revmatoidnem artritisu, granulomatozi s poliangiitisom, mikroskopskem poliangiitisu in navadnem pemfigusu
English: Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
Slovenian: V okviru vzdrževalnega zdravljenja so bolniki prejeli eno infuzijo rituksimaba v odmerku 375 mg/m2 telesne površine vsake 3 mesece do napredovanja bolezni ali največ 2 leti.
English: Psychiatric disorders depression, nervousness,
Slovenian: Psihiatrične motnje potrtost,
English: Table 10b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT) - 48.1 months median observation time Number of Patients
Slovenian: Razmerja ogroženosti za preživetje brez napredovanja bolezni glede na stopnjo po Binetu (ITT) - mediana opazovanja 48,1 meseca.
English: The recommended dosage of Ritemvia for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids.
Slovenian: Priporočeni odmerek zdravila Ritemvia za zdravljenje navadnega pemfigusa je 1.000 mg v intravenski infuziji, ki ji čez dva tedna sledi druga intravenska infuzija 1.000 mg; uporablja se v kombinaciji z glukokortikoidi, katerih odmerke postopoma zmanjšujemo.
English: This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
Slovenian: Ta sindrom ima lahko nekatere značilnosti sindroma razpada tumorja, npr. hiperurikemijo, hiperkaliemijo, hipokalciemijo,
English: • heart failure
Slovenian: +srčna bolezen
English: In an open-label randomised trial, a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m2 in combination with CVP (R-CVP).
Slovenian: V odprtem randomiziranem preskušanju so skupaj 332 predhodno še nezdravljenih bolnikov s folikularnimi limfomi randomizirali na prejemanje kemoterapije CVP (750 mg/m2 ciklofosfamida, 1,4 mg/m2 vinkristina do največ 2 mg 1. dan in 40 mg/m2/dan prednizolona od 1. do 5. dneva) na 3 tedne 8 ciklov, ali na 375 mg/m2 rituksimaba v kombinaciji s CVP (R-CVP).
English: Since hypotension may occur during rituximab administration, consideration should be given to withholding anti-hypertensive medicines 12 hours prior to the rituximab infusion.
Slovenian: Ker se med aplikacijo zdravila rituksimab lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo zdravila rituksimab bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
English: None of the 99 rituximab-treated patients were ADA positive at screening.
Slovenian: Ob presejanju ni imel pozitivnega izvida ADA nobeden od 99 bolnikov, zdravljenih z rituksimabom.
English: The infusion rate may be increased upon improvement of symptoms.
Slovenian: Po izboljšanju simptomov infuzijski pretok ponovno povečamo.
English: The presence of ADA may be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses.
Slovenian: Po drugi infuziji nadaljnjih ciklov so lahko ADA povezana z intenzivnejšimi z infuzijo povezanimi ali alergijskimi reakcijami.
English: In a prospective, open label, international, multicentre, phase III trial 1193 patients with previously untreated advanced follicular lymphoma received induction therapy with R-CHOP (n=881), R-CVP
Slovenian: Predhodno nezdravljeni folikularni limfomi V prospektivnem, odprtem, mednarodnem, multicentričnem preskušanju III. faze je 1193 bolnikov s predhodno nezdravljenimi folikularnimi limfomi prejelo indukcijsko zdravljenje z R-CHOP (n=881), RCVP (n=268) ali R-FCM (n=44) po presoji raziskovalca.
English: The most common IRRs included cytokine release syndrome, flushing, throat irritation, and tremor.
Slovenian: Med najpogostejšimi reakcijami, povezane z infuzijo so bili sindrom sproščanja citokinov, napadi rdečice, draženje žrela in tremor.
English: • being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat and mouth, problems swallowing, constipation, indigestion
Slovenian: bruhanje, driska, bolečine v trebuhu, draženje ali razjede v žrelu in ustih, težave s požiranjem, zaprtost, težave z želodcem,
English: Neither age, sex, lymphoma grade, initial diagnosis, presence nor absence of bulky disease, normal or high LDH nor presence of extranodal disease had a statistically significant effect (Fisher's exact test) on response to rituximab.
Slovenian: Na odgovor na rituksimab naslednji dejavniki niso imeli statistično značilnega vpliva (Fisherjev natančni test): starost, spol, gradus limfoma, začetna diagnoza, prisotnost ali odsotnost obsežne bolezni, normalna ali visoka koncentracija LDH ali ekstranodalna bolezen.
English: Angina pectoris, cardiac arrhythmias such as atrial flutter and fibrillation, heart failure and/or myocardial infarction have occurred in patients treated with rituximab.
Slovenian: Pri bolnikih, zdravljenih z rituksimabom, so se pojavili angina pektoris, srčne aritmije, kot sta atrijska undulacija in fibrilacija, srčno popuščanje in/ali miokardni infarkt.
English: Injury, Poisoning and Procedural Complications
Slovenian: Poškodbe in zastrupitve in zapleti po posegih z infuzijo povezane reakcije2
English: Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes.
Slovenian: Rituksimab se veže specifično na transmembranski antigen, CD20, neglikoziliran fosfoprotein, ki se nahaja na limfocitih pre-B in dozorelih limfocitih B. Antigen je izražen pri > 95% vseh B-celičnih neHodgkinovih limfomov.
English: Progression-free survival (PFS) Overall survival
Slovenian: Preživetje brez napredovanja bolezni (PFS)
English: You must also do this for 12 months after your last treatment with Ritemvia.
Slovenian: Učinkovito kontracepcijsko zaščito morate nadaljevati še 12 mesecev po zadnjem odmerku zdravila Ritemvia.
English: Each mL of concentrate contains 10 mg of rituximab.
Slovenian: En ml koncentrata vsebuje 10 mg rituksimaba.
English: ORR in patients previously treated with autologous bone marrow transplant (ABMT) was 78% versus 43% in patients with no ABMT.
Slovenian: Celokupen odgovor pri bolnikih s predhodno avtologno presaditvijo kostnega mozga je znašal 78 % v primerjavi s 43 % pri bolnikih brez avtologne presaditve kostnega mozga.
English: Log-Rank p value
Slovenian: Vrednost p v testu log-rang
English: A total of 197 patients aged 15 years or older with severe active granulomatosis with polyangiitis (75%) and microscopic polyangiitis (24%) were enrolled and treated in an active-comparator, randomised, double-blind, multicentre, non-inferiority trial.
Slovenian: starih 15 let ali več s hudo, aktivno granulomatozo s poliangiitisom (75 %) in mikroskopskim poliangiitisom (24%).
English: The ADRs listed in Table 3 were all adverse events which occurred at an incidence of ≥ 5% in the rituximab group and at a higher frequency than the comparator group.
Slovenian: Neželeni učinki, navedeni v preglednici 3, so se v skupini, ki je prejemala rituksimab, pojavili z incidenco ≥ 5% in pogosteje kot v primerjalni skupini.
English: Musculoskele tal, connective tissue and bone disorders hypertonia, myalgia, arthralgia, back pain, neck pain, pain
Slovenian: Bolezni mišično skeletnega sistema in vezivnega tkiva hipertonija, mialgija, artralgija, bolečina v hrbtu, bolečina v vratu, bolečina
English: • swelling of the hands or ankles
Slovenian: otekanje rok ali gležnjev.
English: Granulomatosis with polyangiitis and microscopic polyangiitis
Slovenian: Granulomatoza s poliangiitisom in mikroskopski poliangiitis
English: How to store Ritemvia
Slovenian: Shranjevanje zdravila Ritemvia
English: • If you get any side effects talk to your doctor, pharmacist or nurse.
Slovenian: • Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
English: There was no apparent negative impact of the presence of ADA on safety or efficacy in the induction of remission trial.
Slovenian: V preskušanju indukcije remisije prisotnost ADA ni imela opaznega negativnega vpliva na varnost ali učinkovitost.
English: The mean Cmax (N=15) was 408 µg/mL (range, 97 - 764 µg/mL) after the fifth 500 mg/m2
Slovenian: Povprečna Cmax (n = 15) je bila 408 µg/ml (od 97 do 764 µg/ml) po peti infuziji 500 mg/m2, povprečni končni razpolovni čas pa je bil 32 dni (od 14 do 62 dni).
English: B cell levels in human neonates following maternal exposure to rituximab have not been studied in clinical trials.
Slovenian: V kliničnih preskušanjih niso proučevali števila celic B pri novorojenčkih mater, zdravljenih z zdravilom rituksimab.
English: Ritemvia is a clear, colourless solution, supplied as a concentrate for solution for infusion in a glass vial.
Slovenian: Na voljo je v obliki koncentrata za raztopino za infundiranje v stekleni viali.
English: and 6
Slovenian: 6 mesecev.
English: In the induction of remission clinical trial, 24% of patients in the rituximab group (single course) and 23% of patients in the cyclophosphamide group developed CTC grade 3 or greater neutropenia.
Slovenian: V kliničnem preskušanju indukcije remisije se je nevtropenija, ki je bila 3. stopnje ali več po CTC, pojavila pri 24% prejemnikov rituksimaba (en cikel) in pri 23% prejemnikov ciklofosfamida.
English: Adverse drug reaction rituximab + low-dose prednisone (n=38)
Slovenian: Rituksimab + majhen odmerek rednizona (n = 38)
English: Musculoskeletal and Connective Tissue Disorders
Slovenian: Bolezni mišično-skeletnega in vezivnega tkiva mišično-skeletna bolečina
English: The infections were predominately mild to moderate and consisted mostly of upper respiratory tract infections and urinary tract infections.
Slovenian: Večinoma je šlo za blage do zmerne okužbe zgornjih dihal in sečil.
English: Diarrhoea
Slovenian: Cepljenje
English: Blood and lymphatic system disorders neutropenia, leucopenia, +febrile neutropenia, +thrombocytope nia anaemia, +pancytopenia, +granulocytope nia coagulation disorders, aplastic anaemia, haemolytic anaemia, lymphadenopa thy transient increase in serum IgM levels3
Slovenian: Bolezni krvi in limfatičnega sistema nevtropenija, levkopenija, +febrilna nevtropenija, +trombocitopenija anemija, +pancitopenija, +granulocitopenija motnje koagulacije,
English: This medicine may make you more likely to get infections.
Slovenian: Ker prejemate zdravilo Ritemvia, je večja verjetnost, da dobite okužbo.
English: During rituximab maintenance treatment for up to 2 years, leucopenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to observation.
Slovenian: Incidenci levkopenije in nevtropenije 3. ali 4. stopnje sta bili v skupini, ki je prejemala vzdrževalno zdravljenje z rituksimabom do 2 leti, višja (levkopenija: 5%, nevtropenija: 10%) kot v opazovani skupini (levkopenija: 2%, nevtropenija: 4%).
English: Table 11 Treatment of relapsed/refractory chronic lymphocytic leukaemia - overview of efficacy results for rituximab plus FC vs. FC alone (25.3 months median observation time) Efficacy parameter
Slovenian: Zdravljenje kronične limfocitne levkemije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje - pregled rezultatov o učinkovitosti za rituksimab v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC (mediana opazovanja 25,3 meseca).
English: See the Ritemvia package leaflet for more information.
Slovenian: Za več informacij preberite navodilo za uporabo zdravila Ritemvia.
English: Combination therapy
Slovenian: Zdravljenje s kombinacijo zdravil
English: In clinical trials with rituximab monotherapy given for 4 weeks, haematological abnormalities occurred in a minority of patients and were usually mild and reversible.
Slovenian: so se pri manjšem številu bolnikov pojavile hematološke nepravilnosti, ki pa so bile običajno blage in reverzibilne.
English: The overall rate of infection was approximately 94 per 100 patient years in rituximab treated patients.
Slovenian: Okužbe Pri bolnikih, ki so se zdravili z rituksimabom, je bil celokupni delež okužb približno 94 na 100 bolnik-let.
English: Consultation with a neurologist should be considered as clinically indicated.
Slovenian: Glede na klinično stanje pride v poštev posvet z nevrologom.
English: Regular full blood counts, including neutrophil and platelet counts, should be performed during rituximab therapy.
Slovenian: Med zdravljenjem z zdravilom rituksimab je treba redno kontrolirati celotno krvno sliko, vključno s številom nevtrofilcev in trombocitov.
English: Follicular non-Hodgkin's lymphoma
Slovenian: Folikularni ne-Hodgkinov limfom
English: 3infusion related reactions (generalised oedema, bronchospasm, wheezing, laryngeal oedema, angioneurotic oedema, generalised pruritis, anaphylaxis, anaphylactoid reaction)
Slovenian: 3reakcije, povezane z infuzijo (generalizirani edem, bronhospazem, piskanje, edem grla,
English: In the pivotal trial, 166 patients with relapsed or chemoresistant low-grade or follicular B cell NHL received 375 mg/m2 of rituximab as an intravenous infusion once weekly for four weeks.
Slovenian: V ključnem preskušanju je 166 bolnikov, pri katerih se je nizko maligni ne-Hodgkinov limfom ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo, 4 tedne prejemalo po 375 mg/m2 rituksimaba v obliki intravenske infuzije enkrat na teden.
English: Skin and subcutaneous tissue disorders
Slovenian: Bolezni kože in podkožja akne
English: • Information that the product should be administered as IV only to avoid administration route errors.
Slovenian: informacijo, da se lahko zdravilo v izogib napačnim potem uporabe daje le v i.v.
English: Cases of posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS) have been reported.
Slovenian: Poročali so o primerih sindroma posteriorne reverzibilne encefalopatije (posterior reversible encephalopathy syndrome - PRES)/oziroma sindroma reverzibilne posteriorne levkoencefalopatije (reversible posterior leukoencephalopathy syndrome - RPLS).
English: Table 10a First-line treatment of chronic lymphocytic leukaemia Overview of efficacy results for rituximab plus FC vs. FC alone - 48.1 months median observation time Efficacy parameter
Slovenian: Pregled rezultatov o učinkovitosti za rituksimab v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC - mediana opazovanja 48,1 meseca.
English: 1) Estimates were calculated by hazard ratios
Slovenian: Ocena po prirejeni Sharpovi lestvici
English: Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of Ritemvia.
Slovenian: Pred uporabo zdravila Ritemvia mora bolnik vedno dobiti premedikacijo, ki obsega antipiretik in antihistaminik, npr. paracetamol in difenhidramin.
English: 48-months p = 0.0096
Slovenian: 48 mesecev p = 0
English: After a median observation time of 31 months for patients randomised to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed/refractory follicular lymphoma when compared to CHOP (see Table 8).
Slovenian: Pri bolnikih, pri katerih so se folikularni limfomi ponovili ali se bolniki niso odzvali na zdravljenje, in ki so bili v indukcijskem delu zdravljenja randomizirani v skupino R-CHOP, se je po mediani 31-mesečnega opazovanja izid zdravljenja pomembno izboljšal v primerjavi s skupino CHOP (glejte preglednico 8).
English: At 24 months, estimates for overall survival were 68.2% in the R-CHOP arm compared to 57.4% in the CHOP arm. A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 32%.
Slovenian: Nadaljnja analiza trajanja celokupnega preživetja, ki so jo izvedli po mediani časa sledenja 60 mesecev, je potrdila prednost zdravljenja z R-CHOP pred CHOP (p=0,0071), kar pomeni zmanjšanje tveganja za dogodke za 32%.
English: Description of selected adverse drug reactions
Slovenian: Opis izbranih neželenih učinkov Reakcije, povezane z infuzijo
English: Sodium chloride Tri-sodium citrate dihydrate Polysorbate 80
Slovenian: 6.1 Seznam pomožnih snovi natrijev klorid trinatrijev citrat dihidrat polisorbat 80 voda za injekcije
English: Musculo-skeletal disorders arthralgia / musculoskeletal pain, osteoarthritis, bursitis
Slovenian: Bolezni mišično skeletnega sistema in vezivnega tkiva bolečina v sklepu/mišično-skeletna bolečina, osteoartroza,
English: The study showed statistically significant results of rituximab and low-dose prednisone over standarddose prednisone in achieving CRoff ≥ 2 months at month 24 in PV patients (see Table 18).
Slovenian: Študija je pri doseganju CRoff ≥ 2 meseca po 24 mesecih pri bolnikih z navadnim pemfigusom pokazala statistično značilno razliko med shemo rituksimab in majhnega odmerka prednizona ter shemo s standardnim odmerkom prednizona (glejte preglednico 18).
English: Eye disorders lacrimation disorder, conjunctivitis severe vision loss5
Slovenian: Očesne bolezni motnje solzenja, konjunktivitis hudo poslabšanje vida5
English: Further, significantly higher proportion of patients achieved MCIDs for these scores (Table 14).
Slovenian: Poleg tega je značilno večji delež bolnikov dosegel MCID za ti oceni
English: Rituximab should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3).
Slovenian: Zdravila rituksimab se ne sme dajati bolnikom z aktivno, hudo okužbo (npr. tuberkulozo,
English: A small proportion of patients had prolonged peripheral B cell depletion lasting 2 years or more after their last dose of rituximab.
Slovenian: Pri majhnem deležu bolnikov je bil upad števila perifernih celic B
English: Risk Reduction1)
Slovenian: R-CHOP Vrednost p Zmanjšanje tveganja1)
English: log-rank p value hazard ratio (95% CI) risk reduction TNCT (median)
Slovenian: vrednost p v testu log-rang razmerje ogroženosti (95-% IZ) zmanjšanje tveganja TNCT (mediana)
English: Ritemvia 500 mg concentrate for solution for infusion
Slovenian: Ritemvia 500 mg koncentrat za raztopino za infundiranje
English: Keep this card with you for 2 years after your last dose of Ritemvia.
Slovenian: dolgotrajen, trajal je 2 leti ali več po zadnjem odmerku rituksimaba.
English: however transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to rituximab during pregnancy.
Slovenian: Pri nekaterih dojenčkih, katerih matere so med nosečnostjo prejemale rituksimab, pa so poročali o prehodnem zmanjšanju števila celic B in limfocitopeniji.
English: Name:_______________________ Doctor's contact details:________________ Make sure you have a list of all your medicines when you see a health care professional.
Slovenian: Poskrbite, da boste na vsak pregled pri zdravniku prinesli seznam vseh drugih zdravil, ki jih uporabljate.
English: Limited information from one study in relapsed/refractory CLL patients suggests that rituximab treatment may also worsen the outcome of primary hepatitis B infections.
Slovenian: Omejeni podatki iz ene študije pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, kažejo, da lahko zdravljenje z rituksimabom poslabša tudi izid primarnih okužb z virusom hepatitisa B. Pri vseh bolnikih je treba pred začetkom zdravljenja z zdravilom rituksimab narediti presejalni test na virus hepatitisa B. To vključuje najmanj določanje statusa HBsAg in HBcAb, ki ju lahko dopolnimo z ostalimi primernimi označevalci v skladu z lokalnimi smernicami.
English: 1 vial contains 500 mg of rituximab.
Slovenian: 1 viala vsebuje 500 mg rituksimaba.
English: The recommended dose of Ritemvia used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total).
Slovenian: • Ponovitev folikularnih limfomov ali neodzivna bolezen Priporočeni odmerek zdravila Ritemvia za vzdrževalno zdravljenje bolnikov s ponovitvijo folikularnih limfomov ali neodzivno boleznijo, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 3 mesece (z začetkom 3 mesece po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 8 infuzij).
English: % SF‐36 PHS MCID
Slovenian: Povprečna sprememba SF-36 PHS % bolnikov z MCID v SF-36 PHS Povprečna sprememba SF-36 MHS % bolnikov z MCID v SF-36 MHS
English: The safety of immunisation with live viral vaccines, following rituximab therapy has not been studied for NHL and CLL patients and vaccination with live virus vaccines is not recommended.
Slovenian: Varnosti imunizacije z živimi virusnimi cepivi po zdravljenju z zdravilom rituksimab niso proučevali.
English: This includes medicines obtained without a prescription and herbal medicines.
Slovenian: To velja tudi za zeliščna zdravila.
English: Diarrhoea Dyspepsia Constipation
Slovenian: Bolezni prebavil driska dispepsija zaprtje
English: • skin rashes, including acne or spots
Slovenian: slaba prebava, zaprtje, kožni izpuščaji, vključno z aknami ali lisami,
English: Malignancy
Slovenian: burzitis